This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Theis, J. G.W. Articles by Hwang, P. Search for Related Content PubMed PubMed Citation Articles by Theis, J. G.W. Articles by Hwang, P. Social Bookmarking                         What's this?

Interactions of Clobazam With Conventional Antiepileptics in Children

Division of Clinical Pharmacology and Toxicology, The Department of Pediatrics, The Hospital for Sick Children, Toronto

Gideon Koren, MD

Division of Clinical Pharmacology and Toxicology, The Department of Pediatrics, The Hospital for Sick Children, Toronto

Richard Daneman

Division of Clinical Pharmacology and Toxicology, The Department of Pediatrics, The Hospital for Sick Children, Toronto

Allan L. Sherwin, MD, PhD

Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada, Departments of Pediatrics and Pharmacology, The University of Toronto, Toronto, Ontario

Enrique Menzano, MD

Division of Neurology, The Department of Pediatrics, The Hospital for Sick Children, Toronto

Miguel Cortez, MD

Division of Neurology, The Department of Pediatrics, The Hospital for Sick Children, Toronto

Paul Hwang, MD

Division of Neurology, The Department of Pediatrics, The Hospital for Sick Children, Toronto

Clobazam is a 1,5-benzodiazepine effective in antiepileptic therapy of children and adults. Presently it is mainly used as adjuvant therapy for intractable seizures. Our objective was to evaluate the effect of clobazam on the apparent clearance of other antiepileptic drugs at steady state, and to determine the factors that determine the plasma levels of clobazam and its active metabolite N-desmethylclobazam. Patients were 74 children with intractable seizures who received treatment with clobazam at our institution as part of the Canadian Cooperative Clobazam Study Group during the years 1987 to 1991. Serum concentrations of clobazam, N-desmethylclobazam, and of concomitant antiepileptic drugs were monitored and prospectively collected. The effect of clobazam treatment on the apparent clearance steady state of the other antiepileptic drugs was determined by statistical comparison of the clearances of each drug before and after initiation of clobazam treatment using Wilcoxon's signed rank test. The effects of dosage, age, and concomitant antiepileptic therapy on the levels of clobazam and N-desmethylclobazam was assessed by multivariate analysis. Response to treatment and incidence of adverse effects were evaluated for each conventional antiepileptic drug to possibly identify favorable or unfavorable combinations with clobazam. Whereas the clearances of most conventional antiepileptics are not affected by cotherapy with clobazam, the apparent clearances of valproic acid and primidone are significantly reduced in the presence of clobazam. Serum concentrations of clobazam increased with dosage and age, and decreased with phenobarbital cotherapy. Serum concentrations of N-desmethylclobazam significantly correlated with clobazam serum levels, age, or clobazam dosage and were significantly increased by cotherapy with phenytoin or carbamazepine. None of the concomitantly used drugs were associated with increased or decreased rate of seizure control. Twelve patients experienced mild adverse drug effects that were not associated with particular cotherapy, clobazam dose, or plasma concentrations. When clobazam is added to a therapy regimen that includes valproic acid, the patient should be closely followed for possible adverse drug reactions caused by elevated valproic acid serum concentrations, and monitoring of valproate serum levels should be considered. When clobazam doses are gradually increased to achieve an optimal clinical effect, the interactions with phenobarbital, carbamazepine, and phenytoin do not necessitate therapeutic drug monitoring of clobazam or N-desmethylclobazam, because there is a large therapeutic window and a poor correlation between plasma concentrations and therapeutic efficacy. (J Child Neurol 1997; 12:208-213).

Journal of Child Neurology, Vol. 12, No. 3, 208-213 (1997)
DOI: 10.1177/088307389701200311


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Giraud, A. Tran, E. Rey, J. Vincent, J.-M. Treluyer, and G. Pons IN VITRO CHARACTERIZATION OF CLOBAZAM METABOLISM BY RECOMBINANT CYTOCHROME P450 ENZYMES: IMPORTANCE OF CYP2C19 Drug Metab. Dispos., November 1, 2004; 32(11): 1279 - 1286. [Abstract] [Full Text] [PDF]